IDYA: IDEAYA Bio Company Assets

Symbol and logo of brand IDEAYA Bio (IDYA)

IDEAYA Biosciences (IDYA) has achieved a breakthrough in synthetic lethality by developing inhibitors to combat melanoma. The total asset value reflects current resource dynamics, where the 1175.42 metric records fresh values. Ahead lies the race for small molecule development speed supported by Big Pharma and the acceleration of drug modeling via artificial intelligence.

IDEAYA Biosciences, Inc. (IDYA) Company Total Assets: for the period 07/04/2022 - 10/29/2026

Analytical breakdowns and data insights for company IDEAYA Bio (IDYA)

- price and consensus price forecast:
Stock Price ideayabio.com|IDYA - Price Target Chart
- market capitalization data:
Market Value IDEAYA Corp|IDYA - Total Company Value
- book capitalization data:
Equity per Share IDEAYA Biosciences|IDYA - Book Capitalization|Market Cap to Net Assets Ratio ideayabio.com|IDYA - Aggregate Company Assets
- debt and liquidity data:
Debt to Capital IDEAYA Biosciences|IDYA - Long-Term Debt to Equity|Short-Term Debt to Equity IDEAYA Corp|IDYA - Company Debts|Debts to Book Value IDEAYA Corp|IDYA - Company Long-Term Debts|Short-Term Indebtedness IDEAYA Biosciences
General company analysis:IDEAYA Biosciences
Finished products of IDEAYA Corp

Assessing the investment reliability of equity assets begins with an analysis of the resource base, where the total value of assets is calculated inversely through return on assets (ROA) and market capitalization. Amid geopolitical fragmentation limiting IDEAYA Biosciences (IDYA) access to global oncology drug testing networks, the ROA asset trajectory reflects the company's actual ability to scale its material base for the development of targeted cancer treatments.

Who IDEAYA Biosciences competes with

GMAB (genmab.com) - Company Total Assets|Aggregate Company Assets EXEL (Exelixis)|Company Assets NUVL|Aggregate Company Assets Kymera Therapeutics Inc KYMR|Total Business Assets Enliven Corp (ELVN)|ORIC Pharmaceuticals - Company Total Assets|relaytx.com - Cumulative Company Assets|NRIX (Nurix Therapeutics, Inc.) - Aggregate Company Assets|TYRA: Company Assets|Verastem Inc (VSTM) - Aggregate Company Assets|GLUE (Monte Rosa Corp) - Aggregate Company Assets|Aggregate Company Assets CGEM (Cullinan Therapeutics)|Company Assets immuneering.com|CCCC: Company Total Assets|Company Balance Sheet Assets Black Diamond Therapeutics, Inc. BDTX|RPTX: Cumulative Company Assets|PMVP - Company Assets|Cumulative Company Assets Karyopharm (KPTI)|Propanc Biopharma Inc (PPCB) - Aggregate Asset Value|BGMS - Cumulative Company Assets|Aadi Bioscience, Inc. (AADI) - Aggregate Business Assets|ALRN (Aileron Therapeutics Inc) - Company Total Assets|Company Total Assets BPMC|GlycoMimetics, Inc. (GLYC) - Aggregate Company Assets|Aggregate Asset Value springworkstx.com (SWTX)